Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

Hemasphere. 2021 Jun 12;5(7):e606. doi: 10.1097/HS9.0000000000000606. eCollection 2021 Jul.

David G J Cucchi¹, Carolien Van Alphen^{1

2

3}, Sonja Zweegman¹, Bo Van Kuijk¹, Zinia J Kwidama¹, Adil Al Hinai^{4

5}, Alexander A Henneman^{2

3}, Jaco C Knol^{2

3}, Sander R Piersma^{2

3}, Thang V Pham^{2

3}, Connie R Jimenez^{2

3}, Jacqueline Cloos¹, Jeroen J W M Janssen¹

¹ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands.
² OncoProteomics Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands.
³ Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands.
⁴ Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands.
⁵ National Genetic Center, Muscat, Oman.

No abstract available